{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:20:51Z","timestamp":1777944051969,"version":"3.51.4"},"reference-count":60,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Takeda Pharma O\u00dc"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Posttransplant cytomegalovirus (PT-CMV) infection remains a challenging complication and a major cause of morbidity and mortality in transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study surveyed physicians treating solid organ and hematopoietic stem cell transplantation recipients from Central and Eastern European countries. Physician-reported CMV infection prevalence in transplant recipients, treatment regimens, and unmet needs for managing patients with refractory with\/without resistance (R+\/R-) PT-CMV infection were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 164 physicians completed the survey, 23.8% of whom were nephrologists. Physicians estimated that 26.4% of patients who received a transplant in the past 12 months developed PT-CMV infection, of whom 12.9% had refractory R+\/R- PT-CMV infection. On average, 66.5%, 16.5%, and 4.0% of physicians\u2019 current patients with PT-CMV infection received first-, second-, and third- or later-line treatments, respectively. Physicians considered maintenance of CMV viremia clearance (94.5%), good symptom control (94.5%), and lack of renal toxicity (93.9%) as moderately-to-extremely important treatment attributes for managing PT-CMV infection. Compared with other available treatments, more physicians indicated oral valganciclovir to have a strong-to-complete association with these treatment attributes. Overall, 63.4% of physicians indicated some level of satisfaction with conventional refractory R+\/R- PT-CMV treatments. However, 54.9% of physicians reported limited experience with newly approved therapies, such as maribavir. Most physicians considered limited treatment options as a major barrier for improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Survey findings of physicians treating transplant recipients in Central and Eastern Europe suggest the need for increased awareness of newly approved therapies with better efficacy and less toxicity for refractory R+\/R- PT-CMV infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535261440692","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:18:45Z","timestamp":1777465125000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe \u2013 a physician survey"],"prefix":"10.1177","volume":"31","author":[{"given":"Alicja","family":"D\u0119bska-\u015alizie\u0144","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gda\u0144sk"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Todorovi\u0107 Balint","sequence":"additional","affiliation":[{"name":"Clinic of hematology, University Clinical Center of Serbia"},{"name":"Faculty of Medicine, University of Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radovan","family":"Vrhovac","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Unit, University Hospital Centre Zagreb"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Bilji\u0107 Erski","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9666-5374","authenticated-orcid":false,"given":"Tina","family":"Roblek","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.655"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8040213"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01863-8"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(07)09"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12247"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.05.007"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000832"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12655"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22249"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14083"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12006"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12732"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v14.i3.93209"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14183"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12010021"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2046388"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00287-8"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.104211"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005374"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11785"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.03.020"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.01.049"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.04.022"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2599-y"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.01.027"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy696"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30457-X"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001418"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13521"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01787-07"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"e_1_3_8_35_2","volume-title":"Code of Conduct and Adverse Event Reporting Guidelines","author":"European Pharmaceutical Market Research Association (EphMRA)","year":"2025","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of Conduct and Adverse Event Reporting Guidelines. Available from: https:\/\/www.ephmra.org\/code-conduct-aer. 2025, (Accessed April 1, 2026)."},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1460"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01847-2"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2854-2"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00573.x"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.009"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03218-3"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.016"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2023.100804"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02369.x"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2811-2815.2000"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000275"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14216"},{"key":"e_1_3_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.811"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8524"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2021.07.027"},{"key":"e_1_3_8_53_2","volume-title":"American Society for Clinical Pathology 2025","author":"S G","year":"2025","unstructured":"S G. American Society for Clinical Pathology 2025, 2025."},{"key":"e_1_3_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30164-X"},{"key":"e_1_3_8_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1639463"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01612-y"},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.08.017"},{"key":"e_1_3_8_58_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286265"},{"key":"e_1_3_8_59_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00665-0"},{"key":"e_1_3_8_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9317"},{"key":"e_1_3_8_61_2","volume-title":"The root cause of unavailability and delay to innovative medicines: Reducing the time before patients have access to innovative medicines","author":"European Federation of Pharmaceutical Industries and Associations","year":"2023","unstructured":"European Federation of Pharmaceutical Industries and Associations. The root cause of unavailability and delay to innovative medicines: Reducing the time before patients have access to innovative medicines. https:\/\/www.efpia.eu\/media\/677292\/cra-efpia-root-causes-unavailability-delay-080423-final.pdf. 2023, (Accessed April 1, 2026)."}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535261440692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535261440692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535261440692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:44:20Z","timestamp":1777707860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535261440692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/13596535261440692"],"URL":"https:\/\/doi.org\/10.1177\/13596535261440692","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"13596535261440692"}}